Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
3.810
+0.030 (0.79%)
Aug 6, 2026, 9:43 AM EDT - Market open
Opus Genetics Revenue
Opus Genetics had revenue of $755.00K in the quarter ending June 30, 2026, a decrease of -73.80%. This brings the company's revenue in the last twelve months to $9.86M, down -36.09% year-over-year. In the year 2025, Opus Genetics had annual revenue of $14.20M with 29.15% growth.
Revenue (ttm)
$9.86M
Revenue Growth
-36.09%
P/S Ratio
26.05
Revenue / Employee
$427,964
Employees
28
Market Cap
314.58M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.20M | 3.20M | 29.15% |
| Dec 31, 2024 | 10.99M | -8.06M | -42.30% |
| Dec 31, 2023 | 19.05M | -20.80M | -52.20% |
| Dec 31, 2022 | 39.85M | 39.26M | 6,665.70% |
| Dec 31, 2021 | 589.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 75.00K | - | - |
| Dec 31, 2007 | 75.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 215.72M |
| Fulcrum Therapeutics | 80.00M |
| Clinuvel Pharmaceuticals | 64.24M |
| OmniAb | 28.94M |
| Sol-Gel Technologies | 18.47M |
| Fate Therapeutics | 6.32M |
| Vicore Pharma Holding AB | 370.61K |
| SAB Biotherapeutics | 114.70K |
IRD News
- 2 hours ago - Opus Genetics reports Q2 EPS (14c), consensus (16c) - TheFly
- 2 hours ago - Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update - GlobeNewsWire
- 2 hours ago - Opus Genetics Earnings release: Q2 2026 - Filings
- 3 days ago - Opus Genetics enrolls last patient in OPGx-LCA5 trial - TheFly
- 3 days ago - Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease - GlobeNewsWire
- 8 days ago - Opus Genetics initiated with a Buy at TD Cowen - TheFly
- 4 weeks ago - Opus Genetics sets September timeline for retinal disease trial data - TheFly
- 4 weeks ago - Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results - GlobeNewsWire